Lexaria Bioscience Corp. announced its placement in an editorial published by NetworkNewsWire (NNW). Lexaria Bioscience Corp.

began diabetes-related formal studies last year with its DehydraTECH platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.